Oppenheimer Upgrades Incyte to Outperform, Raises Price Target to $144
Oppenheimer analyst Jay Olson upgrades Incyte (NASDAQ:INCY) from Perform to Outperform and raises the price target from $120 to $144.
Share
Why It Matters
An expert analyst thinks Incyte will do better than expected soon. This suggests the company's medicines or business plan look stronger now.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.